Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D38R | ISIN: US0547548588 | Ticker-Symbol: AY20
Lang & Schwarz
06.06.25 | 22:58
1,570 Euro
-100,00 % -1,570
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
AYTU BIOPHARMA INC Chart 1 Jahr
5-Tage-Chart
AYTU BIOPHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,5301,61006.06.

Aktuelle News zur AYTU BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrAYTU BIOPHARMA, INC - 8-K, Current Report1
FrAytu BioPharma sichert sich exklusive Rechte für neues MDD-Medikament2
FrAytu BioPharma secures exclusive rights to new MDD drug3
FrAytu BioPharma, Inc.: Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock247Nantahala Capital Management, Stonepine Capital Management, Aytu Management, and New Institutional Shareholders Lead Financing. DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc. (the...
► Artikel lesen
FrAytu BioPharma, Inc.: Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA Extended-Release Tablets in the United States224Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD") market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD.EXXUA...
► Artikel lesen
DoAYTU BIOPHARMA, INC - S-1/A, General form for registration of securities2
AYTU BIOPHARMA Aktie jetzt für 0€ handeln
MoAytu BioPharma files to sell 6.74M shares of common stock4
MoAYTU BIOPHARMA, INC - S-1, General form for registration of securities3
21.05.AYTU BIOPHARMA, INC - 8-K, Current Report2
15.05.Aytu signals ongoing portfolio expansion opportunities as Q3 2025 revenue surges 32%1
14.05.Aytu BioPharma Non-GAAP EPS of $0.65, revenue of $18.5M beats by $4.76M1
14.05.Aytu BioPharma, Inc.: Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results361Net income of $4.0 million, or $0.65 and $0.21 net income per share basic and diluted, respectivelyAdjusted EBITDA1 of $3.9 millionTotal net revenue of $18.5 million up 32% year-over-yearCompany to...
► Artikel lesen
14.05.AYTU BIOPHARMA, INC - 10-Q, Quarterly Report2
07.05.Aytu BioPharma, Inc.: Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025227DENVER, CO / ACCESS Newswire / May 7, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational...
► Artikel lesen
21.04.Aytu BioPharma, Inc.: Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025300Company to conduct 1x1 meetings on April 24, 2025 DENVER, CO / ACCESS Newswire / April 21, 2025 / Aytu BioPharma,?Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing...
► Artikel lesen
13.02.Aytu BioPharma anticipates positive cash flow with ADHD growth and $2M annual cost savings2
12.02.Aytu BioPharma GAAP EPS of -$0.26 beats by $0.02, revenue of $16.22M beats by $0.67M2
12.02.Aytu BioPharma, Inc.: Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results325Net income of $0.8 millionAdjusted EBITDA1 of $1.3 millionPediatric Portfolio net revenue up 86% sequentiallyFirst quarterly sequential prescription increase for both ADHD and Pediatric portfolios since...
► Artikel lesen
12.02.AYTU BIOPHARMA, INC - 10-Q, Quarterly Report-
12.02.AYTU BIOPHARMA, INC - 8-K, Current Report1
Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1